Article

TP53 mutation and survival in chronic lymphocytic leukemia.

University of Ulm, Ulm, Germany.
Journal of Clinical Oncology (Impact Factor: 18.04). 10/2010; 28(29):4473-9. DOI: 10.1200/JCO.2009.27.8762
Source: PubMed

ABSTRACT The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the impact of TP53 mutations in CLL.
We assessed TP53 mutations by denaturing high-performance liquid chromatography (exons 2 to 11) in a randomized prospective trial (n = 375) with a follow-up of 52.8 months (German CLL Study Group CLL4 trial; fludarabine [F] v F + cyclophosphamide [FC]).
We found TP53 mutations in 8.5% of patients (28 of 328 patients). None of the patients with TP53 mutation showed a complete response. In patients with TP53 mutation, compared with patients without TP53 mutation, median progression-free survival (PFS; 23.3 v 62.2 months, respectively) and overall survival (OS; 29.2 v 84.6 months, respectively) were significantly decreased (both P < .001). TP53 mutations in the absence of 17p deletions were found in 4.5% of patients. PFS and OS for patients with 17p deletion and patients with TP53 mutation in the absence of 17p deletion were similar. Multivariate analysis identified TP53 mutation as the strongest prognostic marker regarding PFS (hazard ratio [HR] = 3.8; P < .001) and OS (HR = 7.2; P < .001). Other independent predictors of OS were IGHV mutation status (HR = 1.9), 11q deletion (HR = 1.9), 17p deletion (HR = 2.3), and FC treatment arm (HR = 0.6).
CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy. Thus, TP53 mutation analysis should be incorporated into the evaluation of patients with CLL before treatment initiation. Patients with TP53 mutation should be considered for alternative treatment approaches.

0 Bookmarks
 · 
81 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in TP53, NOTCH1, and SF3B1 were analyzed in the CLL8 study evaluating first-line therapy with fludarabine and cyclophosphamide (FC) or FC with rituximab (FCR). TP53, NOTCH1, and SF3B1 were mutated in 11.5%, 10.0%, and 18.4% of patients, respectively. While NOTCH1(mut) and SF3B1(mut) virtually showed mutual exclusivity (0.6% concurrence), TP53(mut) was frequently found in NOTCH1(mut) (16.1%) and in SF3B1(mut) (14.0%) patients. There were few significant associations with clinical and laboratory characteristics but genetic markers had strong influence on response and survival. In multivariable analyses, an independent prognostic impact was found for FCR, thymidine kinase (TK) ≥10, unmutated IGHV, 11q deletion, 17p deletion, TP53(mut), and SF3B1(mut) on progression-free survival; and of FCR, age ≥65 years, ECOG performance status ≥0, β2-microglobulin ≥3.5, TK ≥10, unmutated IGHV, 17p deletion, and TP53(mut) on overall survival. Notably, predictive marker analysis identified an interaction of NOTCH1 mutational status and treatment, in that rituximab failed to improve response and survival in patients with NOTCH1(mut). In conclusion, TP53 and SF3B1 mutations appear among the strongest prognostic markers in CLL patients receiving current standard first-line therapy. NOTCH1(mut) was identified as a predictive marker for decreased benefit from the addition of rituximab to FC (FCR). This study is registered at ClinicalTrials.gov, identifier: NCT00281918.
    Blood 03/2014; · 9.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any frontline therapy in the context of a detailed prognostic evaluation, including IGHV, TP53, NOTCH1 and SF3B1 mutations. Median follow-up was 73 (range 2-202) months from disease evaluation. Median treatment-free survival for patients achieving a minimal residual disease negative complete response, minimal residual disease positive complete response, partial response and no response was 76, 40, 11 and 11 months, respectively (P < .001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P < .001), IGHV status (P < .001) and beta2-microglobulin (P = .012). Regarding overall survival, minimal residual disease positivity was predictive of an unfavorable outcome (P = .014), together with advanced age (P < .001), unmutated IGHV status (P = .001), TP53 mutations (P < .001) and elevated beta2-microglobulin (P = .003). In conclusion, for patients requiring frontline therapy, achievement of minimal residual disease negativity is associated with a significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered.
    Haematologica 04/2014; · 5.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Chronic lymphocytic leukemia (CLL) that becomes refractory to chemotherapy is associated with a poor outcome. For these patients, some of the new substances that are currently in clinical development for CLL, seem to offer new hope. These agents include small molecules, new antibodies, immunomodulators, kinase inhibitors, BCL-2 antagonists and chimeric antigen receptor transduced T-cells (CART) and combine high efficacy with a good safety profile. So far, allogeneic stem cell transplantation remains the only curative treatment option for relapsed, refractory CLL patients. However, it is possible that new substances will replace allogeneic stem cell transplantation in the near future. This review provides an overview of the currently available data and an outlook on future therapies for chemotherapy refractory CLL.
    Leukemia & lymphoma 04/2014; · 2.61 Impact Factor